Adaptimmune Therapeutics PLC · OTC:ADAPY

Adaptimmune Therapeutics — Investor Presentation (September 2015)

30 slides from Adaptimmune Therapeutics's investor presentation, Sep 15, 2015

  1. Slide 1: Engineered TCR T cell therapy Presentation Materials September 2015

    Adaptimmune Engineered TCR T cell therapy Presentation Materials September 2015

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o

  3. Slide 3: Investment Highlights

    Investment Highlights Focused on engineered T cell receptors (TCR) for autologous T cell therapeutics to treat cancer Lead clinical candidate, NY-ESO T-cell therapeutic, is in multiple human studies and has shown efficacy in solid tumours and haematologic cancer types Synovial sarcoma – 6 responses

  4. Slide 4: TCR Platform built up over years

    TCR Platform built up over 15 years 1999-2006 Avidex formed on basis of TCR technology from Oxford University Acquired by Medigene (2006) 2008 Adaptimmune formed as a virtual company with UPenn collaboration 2011-2014 Adaptimmune establishes R&D infrastructure and delivers promising clinical data 20

  5. Slide 5: Experienced Management Team and Board

    Experienced Management Team and Board Executive Management Name: Title: Experience: James Noble, MA, FCA CEO & Co-Founder Helen Tayton-Martin, PhD MBA COO & Co-Founder Adrian Rawcliffe CFO Rafael Amado, MD CMO Gwen Binder-Scholl, PhD EVP, Adaptimmune LLC Board of Directors Name: Affiliation: Experie

  6. Slide 6: TCRs recognise intracellular cancer antigens

    TCRs recognise intracellular cancer antigens The TCR is the natural mechanism for T cells to distinguish a diseased cell from a healthy cell All proteins, including intracellular ones, are processed and presented as HLA-peptide complexes which are recognized by TCRs Many cancer targets are intracell

  7. Slide 7: Autologous T cell therapy

    Autologous T cell therapy Blood is taken from a patient, including cells from the immune system Adaptimmune modifies cells from the immune system with enhanced T cell receptors (TCRs) The cells are grown and re-infused to the patient The engineered cells then find and destroy cancer cells Patient Ap

  8. Slide 8: Robust Pipeline of T-Cell Receptors

    NY-ESO TCR MAGE A10 TCR 12 Research Programs 20+ Validated Targets NSCLC Other solid tumors TCR Candidate Rights Research Pre-IND Phase 1/2 Comments First cohort completed Two further cohorts enrolling 1st trial published in NMED 2nd trial (no auto SCT) in 2016 Continuing enrollment Initiating in 20

  9. Slide 9: Large un-partnered pipeline with ability to target almost all major tumors

    Large un-partnered pipeline with ability to target almost all major tumors Adaptimmune GSK 20+ Additional validated targets Twelve new targets selected for development Not yet nominated; programs with work ongoing are excluded Pool of 3: ADAP keeps 2 NY-ESO MAGE-A10 AFP 30+ validated therapeutic tar

  10. Slide 10: Key 2015/2016 Milestones

    Key 2015/2016 Milestones YTD and Anticipated Q1 2015 Additions to Adaptimmune senior leadership team April 2015 AACR presented full cohort data for NY-ESO in Sarcoma and MM May 2015 IPO raises $176m net proceeds Q2 2015 Filing and acceptance of IND for Phase 1/2 studies for MAGE A-10 Q3 2015 Publica

  11. Slide 11: Platform and Differentiation

    Platform and Differentiation

  12. Slide 12: Adaptimmune: The Leader in TCR T-cell Therapy

    Adaptimmune: The Leader in TCR T-cell Therapy Proprietary Technology TCR Engineering Safety Testing Robust Manufacturing Target Validation TCR Gene Delivery T-Cell Isolation T-Cell Expansion Multiple, soluble TCRs Potent and specific Enhanced TCRs Enhanced TCRs Molecular analysis Human Cell testing

  13. Slide 13: Integrated TCR Discovery and Development Platform

    Integrated TCR Discovery and Development Platform Enables ADAP to identify real cancer targets and to engineer and develop T-cell therapeutics against those targets Protected by a combination of patents and know-how Highly differentiated among peers 7. In house R&D and IP 1. Target identification an

  14. Slide 14: NY-ESO in Synovial Sarcoma

    NY-ESO in Synovial Sarcoma > Adaptimmune

  15. Slide 15: Synovial Sarcoma

    Synovial Sarcoma Develops from soft tissues such as muscle, or deep skin tissues Generally incurable - 75% to 80% of patients do not survive past two to three years First line therapy - radiotherapy and chemotherapy, surgical resection where possible FDA granted approval for marketing of Votrient® (

  16. Slide 16: ADAP Phase I/II Study in Synovial Sarcoma

    ADAP Phase I/II Study in Synovial Sarcoma Multicenter pilot study in 11 patients Objectives include Determine the response rate following NY-ESO-1 Specific T cells Persistence and expansion of engineered T-cells and correlate this with clinical response Patients conditioned with high-dose fludarabin

  17. Slide 17: Synovial Sarcoma: Encouraging Response Rate, Tolerability and Persistence

    Synovial Sarcoma : Encouraging Response Rate, Tolerability and Persistence Of the first 10 patients, six responded: only T-cell technology to show clinical anti-tumor response in a solid tumor One complete response, four partial responses, one response at one month Two non responders potentially und

  18. Slide 18: Synovial Sarcoma: Reduction in tumour volume

    ***Surgical resection of primary but still with PR of lung lesions ** Progression of disease from nadir or CR resection of NY-ESO+ lung mets # Low cell dose, late cytokine release syndrome with tumor infiltrating NY-ESO-1+ cells, tumor progression Synovial Sarcoma : Reduction in tumour volume % Chan

  19. Slide 19: Radiographic Pseudoprogression and Response of Lung Metastases

    ADAP Phase I/II Study in Synovial Sarcoma Radiographic Pseudoprogression and Response of Lung Metastases Baseline: Bilateral Miliary Metastatic disease Day +2: Pseudoprogression due to Immune Infilration Day +101: Complete Response Patient 201 NY-ESO C-Reactive Protein AACR April 2015

  20. Slide 20: Partial Response Followed by Tumor Resection in Sarcoma

    NY-ESO TCR T cells administered ADAP Phase I/II Study in Synovial Sarcoma Partial Response Followed by Tumor Resection in Sarcoma One month post NY-ESO TCR T cells Two months post NY-ESO T cells Source: Merchant, CTOS, 2014 ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-

  21. Slide 21: NY-ESO in Multiple Myeloma

    NY-ESO in Multiple Myeloma > Adaptimmune

  22. Slide 22: Multiple Myeloma

    Multiple Myeloma Formed by malignant plasma cells in bone marrow US prevalence: 77,600 cases - approximately 27,000 new cases expected in 2015 Average five-year survival rates are estimated to be less than 45 percent Majority of patients treated with chemotherapy eventually relapse and cannot be fur

  23. Slide 23: ADAP Phase I/II Study in Multiple Myeloma: Study Design

    ADAP Phase I/II Study in Multiple Myeloma Study Design All enrolled patients (n=25) had symptomatic myeloma with active disease High risk population Average of 3 prior Rx Five patients had prior autologous stem cell transplant 12 with cytogenetic abnormalities, including seven categorized as high-ri

  24. Slide 24: Multiple Myeloma: Response Rate Compared to Published Literature

    ADAP Phase I/II Study in Multiple Myeloma Compelling Response Rate Compared to Published Literature Two year overall survival (OS) and progression free survival (PFS) as of April 2015 16/25 patients remain alive; 8/25 remain in remission Median PFS = 19.1 months Median OS = 32.1 months 59 percent (1

  25. Slide 25: Multiple Myeloma: Encouraging Tolerability and Persistence

    ADAP Phase I/II Study in Multiple Myeloma Encouraging Tolerability and Persistence Generally well tolerated - all SAEs possibly related to the NY-ESO T-cells resolved No clinically apparent cytokine release syndrome despite high IL-6 levels CAR-Ts have been associated with severe adverse events attr

  26. Slide 26: MAGE A10 Next proprietary target

    MAGE A10 Next proprietary target

  27. Slide 27: IND for MAGE A-10 TCR therapeutic filed

    IND for MAGE A-10 TCR therapeutic filed Preclinical testing complete NIH RAC approval obtained – March 10, 2015 IND approved – announced July 2, 2015 Initial trial in NSCLC expected to open in 2015 Further indications under consideration: Bladder, Head and Neck, Breast and GI cancers

  28. Slide 28: The GSK Strategic Collaboration

    The GSK Strategic Collaboration Announced June 2014 – Up-front payment £25M GSK has option to license NY-ESO at end of Phase 1/2 studies Adaptimmune conducts all clinical and non-clinical development work Enables Adaptimmune to optimize regulatory, vector, cell processing, analytical, automation, di

  29. Slide 29: Adaptimmune summary

    Adaptimmune (NASDAQ: ADAP) Clinical stage biopharmaceutical company located in Oxfordshire, UK and Philadelphia, PA Well capitalized with 70.8M shares outstanding: ~$300M pro forma cash in F1 Developing engineered T-cell receptors (TCRs) to target cancer cells which the natural immune system cannot

  30. Slide 30: Engineered TCR T cell therapy Presentation Materials September 2015

    Adaptimmune Engineered TCR T cell therapy Presentation Materials September 2015

Adaptimmune Therapeutics — Investor Presentation (September 2015) on 6ix